These results suggest that sleep-disordered breathing is highly prevalent, with important public health outcomes, and that the definition of the disorder should be revised.įaculty of Biology and Medicine of Lausanne, Lausanne University Hospital, Swiss National Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire Vaudoise.Ĭopyright © 2015 Elsevier Ltd. The high prevalence of sleep-disordered breathing recorded in our population-based sample might be attributable to the increased sensitivity of current recording techniques and scoring criteria. After multivariable adjustment, the upper quartile for the apnoea-hypopnoea index (>20♶ events per h) was associated independently with the presence of hypertension (odds ratio 1♶0, 95% CI 1♱4-2♲6 p=0♰292 for trend across severity quartiles), diabetes (2♰0, 1♰5-3♹9 p=0♰467), metabolic syndrome (2♸0, 1♸6-4♲9 p<0♰001), and depression (1♹2, 1♰1-3♶4 p=0♰292). The prevalence of moderate-to-severe sleep-disordered breathing (≥15 events per h) was 23♴% (95% CI 20♹-26♰) in women and 49♷% (46♶-52♸) in men. The median apnoea-hypopnoea index was 6♹ events per h (IQR 2♷-14♱) in women and 14♹ per h (7♲-27♱) in men. The primary outcome was prevalence of sleep-disordered breathing, assessed by the apnoea-hypopnoea index.
Participants underwent complete polysomnographic recordings at home and had extensive phenotyping for diabetes, hypertension, metabolic syndrome, and depression. 1024 (48%) participants were men, with a median age of 57 years (IQR 49-68, range 40-85) and mean body-mass index (BMI) of 25♶ kg/m(2) (SD 4♱). Polysomnography data from 2121 people were included in the final analysis. We invited a cohort of 3043 consecutive participants of the CoLaus/Ps圜oLaus study to take part. Taking into account improvements in recording techniques and new criteria used to define respiratory events, we aimed to assess the prevalence of sleep-disordered breathing and associated clinical features in a large population-based sample.īetween Sept 1, 2009, and June 30, 2013, we did a population-based study (HypnoLaus) in Lausanne, Switzerland. However, its prevalence has mainly been selectively studied in populations at risk for sleep-disordered breathing or cardiovascular diseases. Sleep-disordered breathing is associated with major morbidity and mortality.
Thirdly, we explored in a clinical population the utility of bladder diary based parameters by asking the question: when nocturia improves, which of these parameters improve most? Based on the above explorations the Think Tank summarized elements of the current definitions that need reconsideration and suggests proposals for further research to reach more practical and more clinically meaningful definitions. Secondly, the utility of several nocturnal polyuria definitions was tested in a real life population in relation to the symptom nocturia, in order to display weaknesses of these definitions.
First, discussions identified theoretical and practical shortcomings of current definitions. The report is organized into sections pertaining to the main topic of discussion focussing on the question as to whether a new definition and classification of nocturia and nocturnal polyuria would improve the outcome of management in our patients. The following is a report of the proceedings of the Nocturia Think Tank sessions of the annual International Consultation on Incontinence-Research Society, which took place September 22-24, 2014 in Bristol, UK. The exploration of appropriate dose for female patients, and other influential factors, such as age should be conducted and considered in future. The number of total adverse events was similar in both desmopressin and control groups, otherwise, showed no significant difference between different ODT dose groups (P = 0.82).ĭesmopressin had certain efficacy and adequate safety in women with nocturia. Overall, the risk ratios (RR) for 33% responder rate showed significance when compared with desmopressin to controls. The number of nocturnal voids per night was significantly decreased by desmopressin when compared to the control, and the difference between these three doses ODT was not significant (P = 0.15). The methodological quality of these trials was fair, and four studies had low risk of bias. Seven publications with seven trials were included in this review.
This review also stratified each outcome by dose ( 25 μg) to explore the differences in the dose response for orally disintegrating tablet (ODT). The meta-analysis was performed by Revman 5.3.
Nocturnal polyuria trial#
The PubMed, EMBASE, ISI web of knowledge, and the Cochrane Controlled Trial Register of Controlled Trials were searched from their inception date till April, 2019. To evaluate the efficacy and safety of desmopressin treatment in women with nocturia.
0 kommentar(er)
